Bayer and Burning Rock collaborate to increase patient access to precision cancer medicines

May 30, 2024

https://www.globenewswire.com/news-release/2024/05/30/2890449/0/en/Bayer-and-Burning-Rock-collaborate-to-increase-patient-access-to-precision-cancer-medicines.html

GUANGZHOU, China, May 30, 2024 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ:BNR and LSE:BNR, the “Company” or “Burning Rock”) has recently announced a collaboration with Bayer to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx), aiming to provide diagnostic methods, to enable treatment choice for patients with cancer in China, while driving innovation and development in cancer therapy. This collaboration will focus on the development of companion diagnostic products in China, jointly developing NGS-based CDx for Bayer’s growing portfolio of precision cancer therapies.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.